⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Maria MeraD.O.

Hospitalist · Wilkes Barre, PA 18702

NPI: 1427118454

Share:

36

🟠 Elevated

🤖 ML Fraud Detection Score: 90%

Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.

Learn more →

Risk Flags

High long-acting opioid rate vs peersHigh antipsychotic prescribing (65+)Opioid + benzodiazepine co-prescriberExtreme fills per patient

Risk indicators are statistical patterns, not allegations. Learn more

25,916

Total Claims

$1.3M

Drug Cost

317

Beneficiaries

$3,993

Cost/Patient

Risk Score Breakdown 36/100

Low (0)Moderate (15)Elevated (30)High (50+)
Elderly antipsychotic prescribing+10
Long-acting opioid rate+8
Opioid + benzodiazepine combo+8
High fills per patient+5

Score components are additive. Read full methodology

Peer Comparison vs. 16,767 Hospitalist providers

-61%

Opioid rate vs peers

1.2% vs 3.0% avg

+835%

Cost per patient vs peers

$3,993 vs $427 avg

+137%

Brand preference vs peers

12.4% vs 5.2% avg

⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.

⚠️ Opioid + Benzodiazepine Co-Prescriber

This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.

🔎 Data Overview

🤖

ML fraud detection score of 90% indicates prescribing patterns with significant similarity to confirmed fraud cases. 18 out of 20 decision trees flagged this provider.

💰

Cost per patient is 835% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.

⚠️

This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

1.2%

Opioid Rate

306

Opioid Claims

$16K

Opioid Cost

14.1%

Long-Acting Rate

Brand vs Generic

88% generic

Brand: 3,198 claims · $939K

Generic: 22,549 claims · $314K

Top Prescribed Drugs

Drug (Generic)ClaimsCost
Apixaban1,013$226K
Insulin Aspart135$70K
Rivaroxaban119$37K
Pimavanserin Tartrate16$36K
Insulin Aspart76$35K
Rifaximin22$34K
Mirabegron231$33K
Semaglutide33$32K
Fluticasone/Umeclidin/Vilanter38$29K
Dulaglutide23$22K
Sitagliptin Phosphate65$20K
Insulin Glargine,hum.Rec.Anlog74$19K
Linagliptin59$18K
Empagliflozin51$18K
Umeclidinium Brm/Vilanterol Tr49$18K

Prescribing Profile

193

Unique Drugs

$420K

IRA Negotiated Drugs

$63K

GLP-1 Drugs

36.0

Anomaly Score

Patient Profile

74

Avg Age

62%

Female

2.35

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About